Loading...
Loading...
SLNO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.5M |
| Operating Expense | 23.5M |
| Operating I/L | -21.4M |
| Other Income/Expense | 2.1M |
| Interest Income | 2.1M |
| Pretax | -21.4M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -21.4M |
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel therapeutics for rare diseases. Its primary revenue-generating product is Diazoxide Choline Controlled-Release, an oral tablet designed for the treatment of Prader-Willi Syndrome. The company's focus is on advancing this product through an ongoing Phase III clinical development program, aiming to bring it to market as a once-daily treatment option for patients with this rare condition.
